These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 32001367)

  • 21. Peanut Allergen Powder-dnfp: A Novel Oral Immunotherapy to Mitigate Peanut Allergy.
    Dougherty JA; Wagner JD; Stanton MC
    Ann Pharmacother; 2021 Mar; 55(3):344-353. PubMed ID: 32718178
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oral immunotherapy for peanut allergy in clinical practice is ready.
    Mansfield LE
    Allergy Asthma Proc; 2013; 34(3):205-9. PubMed ID: 23676569
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Peanut allergen powder (Palforzia).
    Med Lett Drugs Ther; 2020 Mar; 62(1593):33-34. PubMed ID: 32555119
    [No Abstract]   [Full Text] [Related]  

  • 24. Oral Immunotherapy for Peanut Allergy.
    Anagnostou K; Clark A
    Annu Rev Med; 2016; 67():375-85. PubMed ID: 26332004
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An update on the controversy around offering oral immunotherapy to peanut-allergic children outside of research.
    Soller L; Abrams EM; Chan ES
    Ann Allergy Asthma Immunol; 2019 Jun; 122(6):559-562. PubMed ID: 30794857
    [No Abstract]   [Full Text] [Related]  

  • 26. Peanut Allergen Threshold Study (PATS): Novel single-dose oral food challenge study to validate eliciting doses in children with peanut allergy.
    Hourihane JO; Allen KJ; Shreffler WG; Dunngalvin G; Nordlee JA; Zurzolo GA; Dunngalvin A; Gurrin LC; Baumert JL; Taylor SL
    J Allergy Clin Immunol; 2017 May; 139(5):1583-1590. PubMed ID: 28238744
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Beyond allergen avoidance: update on developing therapies for peanut allergy.
    Li XM
    Curr Opin Allergy Clin Immunol; 2005 Jun; 5(3):287-92. PubMed ID: 15864090
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Peanut oral immunotherapy dose variations do not result in allergic reactions.
    Anvari S; Tran D; Nguyen A; Devaraj S; Davis CM
    Pediatr Allergy Immunol; 2018 Mar; 29(2):218-220. PubMed ID: 29168272
    [No Abstract]   [Full Text] [Related]  

  • 29. Towards immunotherapy for peanut allergy.
    Pons L; Palmer K; Burks W
    Curr Opin Allergy Clin Immunol; 2005 Dec; 5(6):558-62. PubMed ID: 16264338
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Peanut gastrointestinal delivery oral immunotherapy in adolescents: Results of the build-up phase of a randomized, double-blind, placebo-controlled trial (PITA study).
    Fauquert JL; Michaud E; Pereira B; Bernard L; Gourdon-Dubois N; Rouzaire PO; Rochette E; Merlin E; Evrard B;
    Clin Exp Allergy; 2018 Jul; 48(7):862-874. PubMed ID: 29665158
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Unmet needs of children with peanut allergy: Aligning the risks and the evidence.
    Chan ES; Dinakar C; Gonzales-Reyes E; Green TD; Gupta R; Jones D; Wang J; Winders T; Greenhawt M
    Ann Allergy Asthma Immunol; 2020 May; 124(5):479-486. PubMed ID: 32007568
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The clinical and immunological effects of Pru p 3 sublingual immunotherapy on peach and peanut allergy in patients with systemic reactions.
    Gomez F; Bogas G; Gonzalez M; Campo P; Salas M; Diaz-Perales A; Rodriguez MJ; Prieto A; Barber D; Blanca M; Torres MJ; Mayorga C
    Clin Exp Allergy; 2017 Mar; 47(3):339-350. PubMed ID: 28160513
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oral immunotherapy using polymeric nanoparticles loaded with peanut proteins in a murine model of fatal anaphylaxis.
    Gamazo C; García-Azpíroz M; Souza Rebouças J; Gastaminza G; Ferrer M; Irache JM
    Immunotherapy; 2017 Nov; 9(15):1205-1217. PubMed ID: 29130802
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunotherapy using algal-produced Ara h 1 core domain suppresses peanut allergy in mice.
    Gregory JA; Shepley-McTaggart A; Umpierrez M; Hurlburt BK; Maleki SJ; Sampson HA; Mayfield SP; Berin MC
    Plant Biotechnol J; 2016 Jul; 14(7):1541-50. PubMed ID: 26801740
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Estimation of Health and Economic Benefits of Commercial Peanut Immunotherapy Products: A Cost-effectiveness Analysis.
    Shaker M; Greenhawt M
    JAMA Netw Open; 2019 May; 2(5):e193242. PubMed ID: 31050778
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Epicutaneous immunotherapy for peanut allergy modifies IgG
    Koppelman SJ; Peillon A; Agbotounou W; Sampson HA; Martin L
    J Allergy Clin Immunol; 2019 Mar; 143(3):1218-1221.e4. PubMed ID: 30389411
    [No Abstract]   [Full Text] [Related]  

  • 37. Specific oral tolerance induction in childhood.
    Peters RL; Dang TD; Allen KJ
    Pediatr Allergy Immunol; 2016 Dec; 27(8):784-794. PubMed ID: 27496561
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Investigation of peanut oral immunotherapy with CpG/peanut nanoparticles in a murine model of peanut allergy.
    Srivastava KD; Siefert A; Fahmy TM; Caplan MJ; Li XM; Sampson HA
    J Allergy Clin Immunol; 2016 Aug; 138(2):536-543.e4. PubMed ID: 27130858
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Complexities of Early Peanut Introduction for the Practicing Allergist.
    Greenhawt MJ; Fleischer DM; Atkins D; Chan ES
    J Allergy Clin Immunol Pract; 2016; 4(2):221-5. PubMed ID: 26968960
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Using data from food challenges to inform management of consumers with food allergy: A systematic review with individual participant data meta-analysis.
    Patel N; Adelman DC; Anagnostou K; Baumert JL; Blom WM; Campbell DE; Chinthrajah RS; Mills ENC; Javed B; Purington N; Remington BC; Sampson HA; Smith AD; Yarham RAR; Turner PJ
    J Allergy Clin Immunol; 2021 Jun; 147(6):2249-2262.e7. PubMed ID: 33571537
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.